JP2022509091A5 - - Google Patents
Info
- Publication number
- JP2022509091A5 JP2022509091A5 JP2021527206A JP2021527206A JP2022509091A5 JP 2022509091 A5 JP2022509091 A5 JP 2022509091A5 JP 2021527206 A JP2021527206 A JP 2021527206A JP 2021527206 A JP2021527206 A JP 2021527206A JP 2022509091 A5 JP2022509091 A5 JP 2022509091A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- pharmaceutically acceptable
- acceptable salt
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769196P | 2018-11-19 | 2018-11-19 | |
| US62/769,196 | 2018-11-19 | ||
| US201962821314P | 2019-03-20 | 2019-03-20 | |
| US62/821,314 | 2019-03-20 | ||
| US201962848773P | 2019-05-16 | 2019-05-16 | |
| US62/848,773 | 2019-05-16 | ||
| US201962883313P | 2019-08-06 | 2019-08-06 | |
| US62/883,313 | 2019-08-06 | ||
| PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509091A JP2022509091A (ja) | 2022-01-20 |
| JP2022509091A5 true JP2022509091A5 (cg-RX-API-DMAC10.html) | 2023-07-26 |
| JP7509772B2 JP7509772B2 (ja) | 2024-07-02 |
Family
ID=68848454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527206A Active JP7509772B2 (ja) | 2018-11-19 | 2019-11-18 | ヘモグロビンのモジュレーター |
Country Status (29)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| WO2021202284A1 (en) * | 2020-03-31 | 2021-10-07 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| BR112023021606A2 (pt) * | 2021-05-14 | 2023-12-19 | Global Blood Therapeutics Inc | Formas sólidas de modulador de hemoglobina |
| AR126648A1 (es) * | 2021-05-14 | 2023-11-01 | Global Blood Therapeutics Inc | Métodos para hacer un modulador de hemoglobina |
| JP2024527819A (ja) | 2021-07-19 | 2024-07-26 | バイオアプリケーションズ インコーポレイテッド | 植物由来のｃｏｖｉｄ－１９変異組換えスパイクタンパク質発現ベクターおよび該発現ベクターを用いた組換えタンパク質 |
| MX2024007064A (es) * | 2021-12-10 | 2024-06-20 | Global Blood Therapeutics Inc | Metodos de administracion de un modulador de hemoglobina. |
| EP4727555A1 (en) | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
| WO2025262596A1 (en) * | 2024-06-20 | 2025-12-26 | Pfizer Inc. | Methods of making osivelotor |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| IT1133025B (it) | 1979-06-29 | 1986-07-09 | Wellcome Found | Nuovi eteri per uso farmaceutico e procedimento per la loro preparazione |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| IL64573A (en) | 1980-12-18 | 1985-04-30 | Wellcome Found | Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| CN1245381C (zh) | 1998-12-14 | 2006-03-15 | 弗·哈夫曼-拉罗切有限公司 | 苯基甘氨酸衍生物 |
| WO2000058288A1 (de) | 1999-03-31 | 2000-10-05 | Basf Aktiengesellschaft | Pyridin-2,3-dicarbonsäurediamide |
| MXPA05001544A (es) | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
| ATE527238T1 (de) | 2002-12-04 | 2011-10-15 | Univ Virginia Commonwealth | Mittel mit wirkung gegen sichelzellenanämie |
| CA2526204A1 (en) | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| CA2563752A1 (en) | 2004-04-22 | 2005-11-03 | Allos Therapeutics, Inc. | Compositions of allosteric hemoglobin modifiers and methods of making the same |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| WO2008066145A1 (en) | 2006-11-30 | 2008-06-05 | R-Tech Ueno, Ltd. | Thiazole derivative and use thereof as vap-1 inhibitor |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| KR101538822B1 (ko) | 2008-05-08 | 2015-07-22 | 노바 사우쓰이스턴 유니버시티 | 혈관 내피 성장 인자 수용체에 대한 특이적 억제제 |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) * | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20151907A1 (es) * | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| JP6426694B2 (ja) * | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| WO2015031284A1 (en) | 2013-08-26 | 2015-03-05 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
-
2019
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 IL IL283128A patent/IL283128B2/en unknown
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 SM SM20220106T patent/SMT202200106T1/it unknown
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
- 2019-11-18 TW TW108141848A patent/TWI841630B/zh active
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en not_active Ceased
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 AU AU2019383960A patent/AU2019383960B2/en active Active
- 2019-11-18 CN CN201980088809.5A patent/CN113316568B/zh active Active
- 2019-11-18 KR KR1020217018851A patent/KR102842589B1/ko active Active
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 JP JP2021527206A patent/JP7509772B2/ja active Active
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-17 SA SA521422031A patent/SA521422031B1/ar unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en not_active Abandoned
-
2025
- 2025-12-16 US US19/421,948 patent/US20260103454A1/en active Pending